Trivest Advisors LTD Summit Therapeutics Inc. Transaction History
Trivest Advisors LTD
- $1.1 Billion
- Q1 2025
A detailed history of Trivest Advisors LTD transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Trivest Advisors LTD holds 47,000 shares of SMMT stock, worth $1.19 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
47,000Holding current value
$1.19 Million% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
235Shares Held
83.7MCall Options Held
1.64MPut Options Held
2.55M-
Baker Bros. Advisors LP New York, NY24.4MShares$620 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$296 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$201 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$167 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$142 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.11B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...